Vext Science Past Earnings Performance
Past criteria checks 0/6
Vext Science has been growing earnings at an average annual rate of 1.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 10.5% per year.
Key information
1.2%
Earnings growth rate
-2.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 10.5% |
| Return on equity | -8.0% |
| Net Margin | -20.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vext Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 33 | -7 | 16 | 0 |
| 31 Mar 24 | 34 | -2 | 14 | 0 |
| 31 Dec 23 | 35 | 4 | 14 | 0 |
| 30 Sep 23 | 35 | 5 | 8 | 0 |
| 30 Jun 23 | 34 | 7 | 8 | 0 |
| 31 Mar 23 | 34 | 9 | 10 | 0 |
| 31 Dec 22 | 35 | 11 | 10 | 0 |
| 30 Sep 22 | 37 | 6 | 9 | 0 |
| 30 Jun 22 | 38 | 6 | 7 | 0 |
| 31 Mar 22 | 39 | 6 | 7 | 0 |
| 31 Dec 21 | 37 | 5 | 6 | 0 |
| 30 Sep 21 | 34 | 5 | 6 | 0 |
| 30 Jun 21 | 33 | 5 | 6 | 0 |
| 31 Mar 21 | 30 | 4 | 5 | 0 |
| 31 Dec 20 | 25 | 2 | 5 | 0 |
| 30 Sep 20 | 22 | 0 | 6 | 0 |
| 30 Jun 20 | 20 | 0 | 6 | 0 |
| 31 Mar 20 | 20 | 0 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 5 | 0 |
| 30 Sep 19 | 23 | 4 | 4 | 0 |
| 30 Jun 19 | 23 | 5 | 4 | 0 |
| 31 Mar 19 | 21 | 4 | 3 | 0 |
| 31 Dec 18 | 18 | 4 | 3 | 0 |
| 31 Dec 17 | 15 | 4 | 2 | 0 |
Quality Earnings: VV5 is currently unprofitable.
Growing Profit Margin: VV5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VV5 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare VV5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VV5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: VV5 has a negative Return on Equity (-7.97%), as it is currently unprofitable.